The oral analgesics segment held about half of the market share in 2015, and is anticipated to maintain this trend throughout the forecast period.

Portland, OR -- (SBWire) -- 02/27/2018 --This is mainly attributed to the higher use of oral analgesics as compared to intravenous and topical analgesics. Economical cost, ease of availability, and high popularity of oral analgesics are the key factors responsible for the dominance of this segment.

Get PDF Brochure For Details: https://www.alliedmarketresearch.com/request-sample/1254

Global Analgesics Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $26.4 billion by 2022, registering a CAGR of 7.7% during the period 2015-2022. The non-opioids segment would continue to be the highest revenue-generating segment throughout the forecast period. North America and Europe, are likely to continue their lead through 2022; they collectively accounted for over half of the overall market share in the global analgesics market in 2015.

Frequent pain and aches experienced by the ageing population, increasing incidences of cardiovascular disease (CVD), cancer, & arthritis, and rising investments in R&D by the public & private sectors, with key focus on the classes of compounds to formulate new therapeutics, are the major factors boosting the market growth. However, factors such as uncontrolled prescriptions of opioids and drug abuse, leading to approximately 28,000 deaths in the U.S. every year, and insufficient regulatory guidelines, especially against opioid analgesics, are likely to impede the market growth. Furthermore, the increase in popularity of personalized medicine is expected to provide numerous growth opportunities for the analgesics market in the near future.

Connect to analyst: https://www.alliedmarketresearch.com/connect-to-analyst/1254

Opioid drugs are the strongest types of painkillers, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only. Different type of pain such as phantom, neuropathic pain and cancer pain would encourage drug discovery. Pain including inflammatory pain, surgical pain, physiologic pain and wound care pain would contribute to the growing demand for analgesics drugs.

Companies adopt acquisition as their key development strategy in the analgesics industry to increase their market share. A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.

Enquiry About Report: https://www.alliedmarketresearch.com/purchase-enquiry/1254

North America accounted for a major share of the overall analgesics market revenue in 2015, owing to a large number of pharmaceutical companies in this region. The analgesics market in developing economies, such as China and India, has numerous growth opportunities because of the availability of cheap raw materials and economical workforce. The global analgesics manufacturers are relocating their facilities into developing economies by agreements or acquisitions with local players. Moreover, increasing use of analgesics in countries such as Nigeria, China, and India supports the growth of analgesics in developing economies.

The key companies profiled in the report are Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi S.A.